To conclude, the current study clarifies the significance of PRGs in the prognosis of HNSCC by developing a prognostic signature that may improve the prediction of patient survival and identifying TGM2 as a potential therapeutic target, thereby providing insights into the immune landscape of HNSCC. The gene discussed is TGM2; the disease is head and neck squamous cell carcinoma.